{"id":3853,"date":"2025-03-31T18:11:51","date_gmt":"2025-03-31T18:11:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/clonazepam-txt\/"},"modified":"2025-03-31T18:11:51","modified_gmt":"2025-03-31T18:11:51","slug":"clonazepam-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/clonazepam-txt\/","title":{"rendered":"Clonazepam.txt"},"content":{"rendered":"

Clonazepam<\/h1>\n

CLINICAL USE <\/H3>
\nBenzodiazepine:Anticonvulsant Anxiolytic Restless legs syndrome

DOSE IN NORMAL RENAL FUNCTION <\/H3>Oral: 0.5\u201320 mg daily in 3\u20134 divided doses or as a single dose at night once on maintenance therapy; normal maintenance dose: 4\u20138 mg dailyIV: 1 mg, repeated if necessary Restless legs syndrome: 0.5\u20134 mg at night

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :315.7<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :86<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <0.5<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :3<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :20\u201360\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Start at low dose and increase according to response
  • 10 to 20 &nbsp &nbsp : Start at low dose and increase according to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start at low dose and increase according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR=10\u201320 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAntibacterials: metabolism possibly increased by rifampicinAntipsychotics: increased sedative effects Antivirals: increased risk of prolonged sedation with amprenavir; concentration possibly increased by ritonavirDisulfiram: metabolism inhibited, increased sedative effects Sodium oxybate: enhanced effects of sodium oxybate \u2013 avoid

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>IV bolus: reconstitute with 1 mL diluent (water for injection) to give 1 mg in 1 mL solution.

    IV infusion <\/H4>: up to 3 mg (3 amps) added to 250 mL sodium chloride 0.9% or glucose 5%

    Route <\/H4>Oral, IV bolus or infusion

    Rate of Administration <\/H4>IV bolus: 0.25\u20130.5 mg over 1 minute

    Comments<\/H4>

    IV infusion <\/H4> of clonazepam is potentially hazardous (especially if prolonged), calling for close and constant observation; best carried out in specialist centres with ICU facilities. Risks include apnoea, hypotension and deep unconsciousness

    OTHER INFORMATION <\/H4>In long-term administration, active metabolites may accumulate and lower doses should be usedClonazepam is one of several agents that are used in restless leg syndrome, and has also been tried in the management of intractable hiccup where chlorpromazine has failede
    \n","protected":false},"excerpt":{"rendered":"

    Clonazepam CLINICAL USE Benzodiazepine:Anticonvulsant Anxiolytic Restless legs syndrome DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3853","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3853"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3853\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}